Article

Genentech, Alcon 'Best Companies to Work For'

Fortune magazine has named Genentech and Alcon Laboratories to its latest "100 Best Companies to Work For" list.

New York-Fortune magazine has named Genentech and Alcon Laboratories to its latest "100 Best Companies to Work For" list.

South San Francisco, CA-based Genentech, with almost 11,000 employees in the United States, is fifth in the 2008 rankings. The achievement marks the company's 10th consecutive year on the list, a distinction that cannot be claimed by any other biotechnology company, according to Genentech.

This year marks Alcon Laboratories' 10th consecutive time on the list, too. The company, with almost 6,000 employees in the United States, ranks 60th on the 2008 list, five spots up from last year. Alcon Laboratories noted that Fortune cited the company's retirement program, which matches employee contributions 2.4:1, as well as its benefits package, financial compensation, and U.S. headquarters campus in Fort Worth, TX.

The full list appears in the Feb. 4 issue of Fortune magazine and is available at http://www.fortune.com/bestcompanies/.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) CCOI's new CEO Malvina Eydelman, MD, outlines her mission and vision for the organization
CIME 2025: Neda Shamie, MD, on expanding options in pharmacological presbyopia management
At CIME 2025, Neda Shamie, MD, answers questions about Demodex blepharitis
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
© 2025 MJH Life Sciences

All rights reserved.